Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.

Bovis F, De Stefano N, Steinerman JR, Knappertz V, Sormani MP.

Mult Scler. 2019 Feb;25(2):217-223. doi: 10.1177/1352458517743804. Epub 2017 Nov 20.

PMID:
29154721
2.

Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis.

Yamamura T, Ashtamker N, Ladkani D, Fukazawa T, Houzen H, Tanaka M, Miura T, Knappertz V.

Clin Exp Neuroimmunol. 2017 May;8(2):129-137. doi: 10.1111/cen3.12383. Epub 2017 Mar 23.

3.

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.

Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, Steinerman JR, Knappertz V.

Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e358. doi: 10.1212/NXI.0000000000000358. eCollection 2017 Jul.

4.

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.

Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M, Weiner B, Kusko R, Zeskind B, Knappertz V, Grossman I, Hayden MR.

Genome Med. 2017 May 31;9(1):50. doi: 10.1186/s13073-017-0436-y.

5.

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.

Giovannoni G, Cutter G, Sormani MP, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CAM, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, Matthews P, Carassiti D, Baker D, Schmierer K.

Mult Scler Relat Disord. 2017 Feb;12:70-78. doi: 10.1016/j.msard.2017.01.007. Epub 2017 Jan 17. Review.

PMID:
28283111
6.

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V.

Int J MS Care. 2017 Jan-Feb;19(1):16-24. doi: 10.7224/1537-2073.2015-024.

7.

Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study.

Davis MD, Ashtamker N, Steinerman JR, Knappertz V.

Neurol Neuroimmunol Neuroinflamm. 2017 Feb 8;4(2):e327. doi: 10.1212/NXI.0000000000000327. eCollection 2017 Mar.

8.

Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis.

Ziemssen T, Ashtamker N, Rubinchick S, Knappertz V, Comi G.

Expert Opin Drug Saf. 2017 Feb;16(2):247-255. doi: 10.1080/14740338.2017.1274728. Review.

PMID:
27989217
9.

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.

Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6145-E6152. Epub 2016 Sep 26.

10.

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.

Cutter GR, Knappertz V, Sasson N, Ladkani D.

BMC Neurol. 2016 Sep 17;16:176. doi: 10.1186/s12883-016-0702-4.

11.

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.

Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung HP, Comi G, Jeffery DR, Kappos L, Goodin DS, Arnason B.

J Neurol. 2016 Jul;263(7):1418-26. doi: 10.1007/s00415-016-8146-8. Epub 2016 May 13.

12.

Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.

Grossman I, Knappertz V, Laifenfeld D, Ross C, Zeskind B, Kolitz S, Ladkani D, Hayardeny L, Loupe P, Laufer R, Hayden M.

Prog Neurobiol. 2017 May;152:114-130. doi: 10.1016/j.pneurobio.2016.02.001. Epub 2016 Mar 4. Review.

PMID:
26952809
13.

Causes of death among persons with multiple sclerosis.

Cutter GR, Zimmerman J, Salter AR, Knappertz V, Suarez G, Waterbor J, Howard VJ, Marrie RA.

Mult Scler Relat Disord. 2015 Sep;4(5):484-490. doi: 10.1016/j.msard.2015.07.008. Epub 2015 Jul 18.

PMID:
26346799
14.

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.

Wolinsky JS, Borresen TE, Dietrich DW, Wynn D, Sidi Y, Steinerman JR, Knappertz V, Kolodny S; GLACIER Study Group.

Mult Scler Relat Disord. 2015 Jul;4(4):370-6. doi: 10.1016/j.msard.2015.06.005. Epub 2015 Jun 14.

15.

Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S.

Kaufman DW, Reshef S, Golub HL, Peucker M, Corwin MJ, Goodin DS, Knappertz V, Pleimes D, Cutter G.

Mult Scler Relat Disord. 2014 May;3(3):364-71. doi: 10.1016/j.msard.2013.12.003. Epub 2013 Dec 25.

PMID:
25876474
16.

Challenges and opportunities in designing clinical trials for neuromyelitis optica.

Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium.

Neurology. 2015 Apr 28;84(17):1805-15. doi: 10.1212/WNL.0000000000001520. Epub 2015 Apr 3. Review.

17.

Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.

Zivadinov R, Dwyer M, Barkay H, Steinerman JR, Knappertz V, Khan O.

J Neurol. 2015 Mar;262(3):648-53. doi: 10.1007/s00415-014-7616-0. Epub 2014 Dec 27.

PMID:
25542295
18.

Causes of death among commercially insured multiple sclerosis patients in the United States.

Goodin DS, Corwin M, Kaufman D, Golub H, Reshef S, Rametta MJ, Knappertz V, Cutter G, Pleimes D.

PLoS One. 2014 Aug 21;9(8):e105207. doi: 10.1371/journal.pone.0105207. eCollection 2014.

19.

CD19 as a molecular target in CNS autoimmunity.

Stüve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, von Büdingen HC, Centonze D, Forsthuber TG, Knappertz V.

Acta Neuropathol. 2014 Aug;128(2):177-90. doi: 10.1007/s00401-014-1313-z. Epub 2014 Jul 4. Review.

20.

Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study.

Doerner M, Beckmann K, Knappertz V, Kappos L, Hartung HP, Filippi M, O'Connor PW, Arnason B, Cook S, Jeffery D, Comi G, Limmroth V.

Eur Neurol. 2014;71(3-4):173-9. doi: 10.1159/000355530. Epub 2014 Jan 21.

PMID:
24457374
21.

Mortality in patients with multiple sclerosis.

Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC.

Neurology. 2013 Jul 9;81(2):184-92. doi: 10.1212/WNL.0b013e31829a3388. Review.

22.

Interleukin 17F level and interferon β response in patients with multiple sclerosis.

Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C.

JAMA Neurol. 2013 Aug;70(8):1017-21. doi: 10.1001/jamaneurol.2013.192.

23.

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.

Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V.

BMJ Open. 2012 Nov 30;2(6). pii: e001972. doi: 10.1136/bmjopen-2012-001972. Print 2012.

24.

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.

Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H.

Pharmacogenomics J. 2013 Oct;13(5):443-51. doi: 10.1038/tpj.2012.27. Epub 2012 Jun 19.

25.

Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.

Caloyeras JP, Zhang B, Wang C, Eriksson M, Fredrikson S, Beckmann K, Knappertz V, Pohl C, Hartung HP, Shah D, Miller JD, Sandbrink R, Lanius V, Gondek K, Russell MW.

Clin Ther. 2012 May;34(5):1132-44. doi: 10.1016/j.clinthera.2012.03.004. Epub 2012 Apr 27.

PMID:
22541587
26.

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V.

Neurology. 2012 Apr 24;78(17):1315-22. doi: 10.1212/WNL.0b013e3182535cf6. Epub 2012 Apr 11.

27.

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC; 16-Year Long Term Follow-up Study Investigators.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):282-7. doi: 10.1136/jnnp-2011-301178. Epub 2011 Dec 21.

PMID:
22193561
28.

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.

Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V; 16-Year Long-Term Follow-up Study Investigators.

PLoS One. 2011;6(11):e22444. doi: 10.1371/journal.pone.0022444. Epub 2011 Nov 30.

29.

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.

Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C; BEYOND Study Group.

Mult Scler. 2012 Feb;18(2):181-95. doi: 10.1177/1352458511418629. Epub 2011 Sep 27.

PMID:
21952094
30.

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Neurology. 2011 Aug 30;77(9):835-43. doi: 10.1212/WNL.0b013e31822c90d7. Epub 2011 Aug 17. Erratum in: Neurology. 2011 Sep 27;77(13):1317.

PMID:
21849647
31.

Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.

Acaster S, Swinburn P, Wang C, Stemper B, Beckmann K, Knappertz V, Pohl C, Sandbrink R, Gondek K, Edan G, Kappos L, Freedman M, Hartung HP, Arnason B, Comi G, Filippi M, Jeffery D, O'Connor P, Cook S, Lloyd AJ.

Mult Scler. 2011 Dec;17(12):1504-13. doi: 10.1177/1352458511414039. Epub 2011 Jul 14.

PMID:
21757536
32.

Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy.

Curkendall SM, Wang C, Johnson BH, Cao Z, Preblick R, Torres AM, Knappertz V, Gondek K.

Clin Ther. 2011 Jul;33(7):914-25. doi: 10.1016/j.clinthera.2011.05.049.

PMID:
21684600
33.

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.

Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V.

Neurology. 2011 Apr 5;76(14):1222-8. doi: 10.1212/WNL.0b013e3182143577.

34.

Needles: a comparison study.

Mayer G, Knappertz V, Kinast P.

Med Device Technol. 2009 Nov-Dec;20(7):30, 32-4.

PMID:
20058653
35.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
36.

Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage.

Kreiter KT, Mayer SA, Howard G, Knappertz V, Ilodigwe D, Sloan MA, Macdonald RL.

Stroke. 2009 Jul;40(7):2362-7. doi: 10.1161/STROKEAHA.109.547331. Epub 2009 May 21.

PMID:
19461029
37.

An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration.

Fisher M, Cushman M, Knappertz V, Howard G.

Am Heart J. 2008 Jul;156(1):106-11. doi: 10.1016/j.ahj.2007.12.035. Epub 2008 Mar 6.

38.

The dose of aspirin for the prevention of cardiovascular and cerebrovascular events.

Fisher M, Knappertz V.

Curr Med Res Opin. 2006 Jul;22(7):1239-48. Review.

PMID:
16892516
39.

Aspirin and clopidogrel resistance: an emerging clinical entity.

Johns A, Fisher M, Knappertz V.

Eur Heart J. 2006 Jul;27(14):1754; author reply 1754-5. Epub 2006 Jun 2. No abstract available.

PMID:
16751205
40.

Comments in response to "low-dose aspirin increases aspirin resistance in patients with coronary artery disease".

Fisher M, Knappertz V.

Am J Med. 2006 Mar;119(3):287; author reply 287-8. No abstract available.

PMID:
16490484
41.
42.

Early impairment in consciousness predicts mortality after hemispheric ischemic stroke.

Cucchiara BL, Kasner SE, Wolk DA, Lyden PD, Knappertz VA, Ashwood T, Odergren T, Nordlund A; CLASS-I Investigators.

Crit Care Med. 2004 Jan;32(1):241-5.

PMID:
14707586
43.

Lack of hemispheric dominance for consciousness in acute ischaemic stroke.

Cucchiara B, Kasner SE, Wolk DA, Lyden PD, Knappertz VA, Ashwood T, Odergren T, Nordlund A.

J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):889-92.

44.

Carotid Doppler high-intensity transient signals in dilated cardiomyopathy.

Knappertz VA, Tegeler CH, Furberg CD, Wesley DJ, Stewart KP, Kitzman DW.

Am Heart J. 2000 Aug;140(2):E1-4.

PMID:
10925321
45.

Transcranial 3D B-mode imaging in a case of cerebral hemorrhage.

Delcker A, Knappertz VA, Wilson J, Branch C, Bell T, Tegeler C.

J Neuroimaging. 1998 Jul;8(3):173-5.

PMID:
9664856
46.

Vagus nerve imaging with ultrasound: anatomic and in vivo validation.

Knappertz VA, Tegeler CH, Hardin SJ, McKinney WM.

Otolaryngol Head Neck Surg. 1998 Jan;118(1):82-5.

PMID:
9450833
47.

[Volume flow in carotid occlusion. Measurement using ultrasound time domains and color M mode analysis].

Knappertz VA, Tegeler CH, Myers LG.

Ultraschall Med. 1996 Oct;17(5):229-34; discussion 235. German.

PMID:
9064766
48.

Cough headache and the competency of jugular venous valves.

Knappertz VA.

Neurology. 1996 May;46(5):1497. No abstract available.

PMID:
8628521
49.

Middle cerebral artery velocity correlates with nitroglycerin-induced headache onset.

Tegeler CH, Davidai G, Gengo FM, Knappertz VA, Troost BT, Gabriel H, Davis RL.

J Neuroimaging. 1996 Apr;6(2):81-6.

PMID:
8634492
50.

Clinical cerebrovascular applications of arterial ultrasound volume flow rate estimates.

Knappertz VA, Tegeler CH, Myers LG.

J Neuroimaging. 1996 Jan;6(1):1-7.

PMID:
8555656

Supplemental Content

Loading ...
Support Center